---
title: "Obefazimod (ABX464) in Ulcerative colitis: Administration"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Administration. Topics: Oral, once daily in the morning with food; Effect of food on exposure: healthy volunteers, 50 mg. 2 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/administration"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Administration

<a id="heading-2.1.2.10.2"></a>

## 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

### Oral, once daily in the morning with food

> “Administered once daily in the morning with food”
> “Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

> “Subjects will be orally dosed daily in a fed condition (ideally at the same time in the morning) with a glass of water.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

> “Administered once daily, preferably in the morning, with food”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-2.1.2.10.2-2"></a>

### Effect of food on exposure: healthy volunteers, 50 mg

> “The maximum concentration (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0–∞) of ABX464 were demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively).”
> “It was concluded that food has a significant impact on the levels of ABX464 in plasma with a delay in absorption and increased relative bioavailability, with a lesser impact on its biotransformation into ABX464-NGlc.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
